Sabitlenmiş Tweet

$ALLR Something to consider with NFA…. 03/02/26 $2OM 💰 NON-convert/NON-dilute financing is precisely structured to bridge the current Phase 2 (completion + strong data) through regulatory engagement and into pivotal escalation, with clear runway through 2028.
This setup creates an optimal window to pursue BTD (on top of existing 08/2025 Fast Track ) during the funded @US_FDA meeting prep phase, maximizing speed toward approval in platinum-resistant ovarian cancer.
BTD approval is 60 days ⏳⌛️🚀
Phase2 each treatment 28 days cycle.. do they have prep-data and that’s how 20M$ was approved ?
Who would agree to take 20M$ and just sit and wait with NO DATA and PLAN in MOTION…?
Any suggestions @BioValues @IAmBiotech
@IAmBiotech @BPharmCatalyst
@ESGO_society @myESMO
@PSOGI_EC
@IJGConline @ENYGO_official
@AJOG_thegray @gynoncjnls
@oncodaily
@JCO_ASCO @oncodaily
@AmgenOncology @OncoAlert @bioAffinity
English




















